Loading company…
Sichuan Cunde develops cell therapies and products for tumors and liver cirrhosis.
Founded in 2016 and based in Chengdu, China, Sichuan Cunde Therapeutics develops diagnostic and treatment products for major diseases including tumors and liver cirrhosis. Its personalized tumor vaccine platform uses autologous dendritic cells, and its products include therapeutic tumor vaccines and an anti-liver fibrosis macrophage injection. In September 2025, the company raised Series A funding from Dongna Investment.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in